NYSEARCA:PBE Invesco Biotechnology & Genome ETF (PBE) Price, Holdings, & News $66.14 -1.17 (-1.74%) As of 07/11/2025 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartDividendHoldingsOwnershipRatingsShort InterestBuy This Stock About Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get PBE alerts:Sign Up Key Stats Today's Range$66.14▼$66.7950-Day Range$59.58▼$67.3152-Week Range$54.52▼$72.84Volume3,055 shsAverage Volume7,511 shsMarket Capitalization$230.17 millionAssets Under Management$229.54 millionDividend Yield0.24%Net Expense Ratio0.58%Aggregate RatingModerate Buy ETF Overview PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors. Invesco PowerShares Capital Management LLC acts as the Fund's investment adviser. Read More Invesco Biotechnology & Genome ETF ExpensesTypePBEHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.50%0.56%0.56%0.51%0.53%Other Expenses0.08%0.47%0.56%0.59%0.56%Total Expense0.58%0.75%0.76%0.74%0.73%Fee Waiver0.00%-0.67%-0.66%-0.71%-0.63%Net Expense0.58%0.60%0.63%0.58%0.60% Receive PBE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Invesco Biotechnology & Genome ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address PBE ETF News HeadlinesPBE Invesco Biotechnology & Genome ETFJanuary 29, 2025 | seekingalpha.comInvesco Dynamic Biotech & Genome ETF (PBE)August 31, 2024 | uk.finance.yahoo.comA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.July 12 at 2:00 AM | American Alternative (Ad)Invesco Dynamic Biotechnology & Genome ETF declares quarterly distribution of $0.0242March 22, 2024 | msn.com3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough PotentialFebruary 19, 2024 | investorplace.comWhere Are Biotech ETFs Headed After Q4 Earnings?February 14, 2024 | msn.comSee More Headlines PBE ETF - Frequently Asked Questions How have PBE shares performed this year? Invesco Biotechnology & Genome ETF's stock was trading at $66.53 on January 1st, 2025. Since then, PBE shares have decreased by 0.6% and is now trading at $66.14. Who are Invesco Biotechnology & Genome ETF's major shareholders? Top institutional investors of Invesco Biotechnology & Genome ETF include YHB Investment Advisors Inc. (0.70%) and Wealth Enhancement Advisory Services LLC (0.14%). How do I buy shares of Invesco Biotechnology & Genome ETF? Shares of PBE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Invesco Biotechnology & Genome ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Invesco Biotechnology & Genome ETF investors own include Micron Technology (MU), Pfizer (PFE), Devon Energy (DVN), Intel (INTC), Activision Blizzard (ATVI), NVIDIA (NVDA) and Bristol Myers Squibb (BMY). Fund Details IssuerInvesco Fund NameInvesco Biotechnology & Genome ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:PBE Inception Date6/23/2005 Fund ManagerPeter Hubbard, Michael Jeanette, Pratik Doshi, Tony Seisser Webwww.invescopowershares.com Phone+1-800-9830903Fund Focus Asset ClassEquity BenchmarkDynamic Biotech & Genome Intellidex Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings31 Fund Statistics Assets Under Management$233.59 million Average Daily Volume$5.48 thousand Discount/Premium-0.01% Administrator, Advisor and Custodian AdministratorThe Bank of New York Mellon Corporation AdvisorInvesco Capital Management, LLC CustodianThe Bank of New York Mellon Corporation DistributorInvesco Distributors, Inc. Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerCitadel Options OptionableOptionable Options Volume10 Put Options5 Call Options10 Short Interest500 shs Miscellaneous Outstanding Shares3,480,000Beta0.76 Creation Unit10,000 Creation Fee$500.00 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report Top 10 PBE HoldingsIllumina (NASDAQ:ILMN)Holding Weight: 5.53%Alnylam Pharmaceuticals (NASDAQ:ALNY)Holding Weight: 5.18%Royalty Pharma (NASDAQ:RPRX)Holding Weight: 5.14%Vertex Pharmaceuticals (NASDAQ:VRTX)Holding Weight: 5.03%Amgen (NASDAQ:AMGN)Holding Weight: 4.97%Gilead Sciences (NASDAQ:GILD)Holding Weight: 4.86%BioMarin Pharmaceutical (NASDAQ:BMRN)Holding Weight: 4.81%United Therapeutics (NASDAQ:UTHR)Holding Weight: 4.47%Anavex Life Sciences (NASDAQ:AVXL)Holding Weight: 3.73%Blueprint Medicines (NASDAQ:BPMC)Holding Weight: 3.28%Full Holdings DetailsPBE Sector ExposurePBE Industry Exposure This page (NYSEARCA:PBE) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.